RENEW-OP-1
About This Study
To be included in RENEW-OP-1, participants must be / have
18 to 75 years of age
- Have a diagnosis of OUD
- Taking transmucosal buprenorphine
- Willing to comply with all study assessments and procedures
To be included in RENEW-OP-1, participants must not be/have
- Diagnosed schizophrenia, bipolar disorder, borderline personality disorder, or eating disorder
- Opioid overdose in past 6 months
- Current substance use disorder (excluding OUD)
- Pregnant or breastfeeding or planning to become pregnant/breastfeed
Eligibility Criteria
Inclusion Criteria
- 18 to 75 years of age
- Have a diagnosis of OUD
- Taking transmucosal buprenorphine
- Willing to comply with all study assessments and procedures
Exclusion Criteria
- Diagnosed schizophrenia, bipolar disorder, borderline personality disorder, or eating disorder
- Opioid overdose in past 6 months
- Current substance use disorder (excluding OUD)
- Pregnant or breastfeeding or planning to become pregnant/breastfeed
For More About This Study or To Ask About Participation
Abigail Crawford
Clinical Research Coordinator
Additional Information
Dr. Albert Arias is a psychiatrist with over 25 years of clinical and research experience. He is a professor at the Virginia Tech Carilion School of Medicine. He is board certified by American Board of Psychiatry and Neurology in Psychiatry. He completed his residency at the University of Connecticut Health.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study with a Separate Open-label Cohort to Evaluate the Efficacy and Safety of Brenipatide as Adjunctive Treatment to Transmucosal Buprenorphine with or without Naloxone in Early Recovery of Participants with Opioid Use Disorder (RENEW-Op-1)
Industry sponsored by Eli Lilly and Company